THDB(SH:600867)2022-04-18 16:00Financial Performance - The net profit attributable to the parent company for 2021 was CNY 1,378,563,889.56, with a total distributable profit of CNY 2,700,547,905.49 after accounting for dividends paid[2]. - The cash dividend for the year accounted for 45.85% of the net profit attributable to shareholders in the consolidated financial statements[2]. - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares (including tax) to all shareholders, totaling CNY 599,876,577.60[2]. - The company reported a net profit of CNY 1,308,254,212.79 for the year, with a significant portion of profits retained for future distribution[2]. - The company's operating revenue for 2021 was CNY 3,267,897,464.66, representing a year-on-year increase of 12.99% compared to CNY 2,892,169,238.81 in 2020[15]. - Net profit attributable to shareholders for 2021 reached CNY 1,308,254,212.79, a significant increase of 40.69% from CNY 929,916,045.06 in 2020[15]. - The total profit reached CNY 1.5344528 billion, reflecting a year-on-year growth of 38.47%[23]. - The net profit attributable to shareholders was CNY 1.3082542 billion, up 40.69% compared to the previous year[23]. - The company’s total assets at the end of 2021 were CNY 6,520,101,831.69, reflecting a growth of 12.35% from CNY 5,803,260,212.00 at the end of 2020[15]. - Basic earnings per share for 2021 were CNY 0.64, an increase of 39.13% compared to CNY 0.46 in 2020[17]. - The weighted average return on equity for 2021 was 22.08%, an increase of 4.36 percentage points from 17.72% in 2020[17]. Research and Development - The company established an innovation drug R&D center in Hangzhou and introduced three new diabetes treatment drugs in 2021[28]. - The company is expanding its treatment portfolio to include new drugs for gout and hyperuricemia, with clinical trials approved for two new drugs[29]. - The company has achieved full coverage in the research and development of insulin analogs, GLP-1 receptor agonists, and high clinical value oral hypoglycemic drugs, accelerating the progress of its R&D pipeline[32]. - The company completed the production of three batches of insulin analog GLP-1RA compound preparations in 2021 and is conducting stability and non-clinical studies[30]. - The company has made significant progress in the clinical trials of rapid-acting insulin and GLP-1 receptor agonists, with liraglutide injection entering the Pre-NDA stage[39]. - The company is actively enhancing its diabetes management platform and POCT project to improve patient care and communication[25]. - The company is focusing on innovative drug development, with significant investments in multi-target diabetes drugs and small molecule drugs[105]. - The company has ongoing clinical trials for multiple diabetes-related drugs, including THDBH110 and THDBH120[100]. - The company aims to enhance its core competitiveness through increased R&D spending in response to market changes[104]. Market and Sales - The company is positioned as a leader in the insulin market, continuously increasing its market share since breaking the foreign monopoly on insulin in China[50]. - The sales revenue of insulin raw materials and injections reached CNY 2.419 billion, a year-on-year increase of 6.83%[26]. - The sales revenue of insulin analogs raw materials and injections surged to CNY 401 million, marking a 204.79% year-on-year growth[26]. - The company’s insulin product sales volume increased by over 200% year-on-year, with successful bidding in over 3,800 hospitals[25]. - The company is actively expanding its product pipeline in the diabetes treatment sector, including long-acting, medium-acting, and rapid-acting insulin products, as well as GLP-1RA formulations[53]. - The company is focusing on expanding its market presence in the diabetes and hyperuricemia treatment sectors, which are expected to grow significantly in the coming years[89]. Corporate Governance - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, complying with relevant regulations[122]. - The board of directors consists of 9 members, including 3 independent directors, and held 13 board meetings during the reporting period[123]. - The supervisory board is composed of 3 members, including 1 employee representative, and held 6 meetings during the reporting period[123]. - The company has established and optimized internal control systems to enhance risk prevention capabilities and operational standards[123]. - The company maintains a commitment to fair treatment of all investors and actively engages in investor relations through various channels[123]. Environmental Responsibility - The company reported a total wastewater discharge of 364,853 m³ for the year 2021, with COD concentration at 24.9875 mg/L, well below the permitted limit of 80 mg/L[171]. - The company generated a total of 45.313 tons of hazardous waste in 2021, all of which was legally disposed of by a licensed hazardous waste management unit[171]. - The company has implemented a comprehensive emergency plan for environmental incidents, which was revised in 2023[179]. - The company has established a stable operation of pollution prevention facilities, achieving over 95% removal efficiency for sulfur dioxide[176]. - The company has invested over 100 million yuan in environmental protection initiatives from 2018 to mid-2022, focusing on wastewater treatment upgrades and waste gas treatment facilities[185]. Employee and Talent Management - The company has a diverse workforce with 1,188 sales personnel and 516 technical staff[154]. - The company emphasizes employee training programs to enhance overall quality and work efficiency[157]. - The company has strengthened its human resources system, introducing key talents such as the Vice President of R&D and Chief Human Resources Officer to enhance overall team capability[45]. - The company is focused on expanding its talent pool and improving employee training to support its rapid growth and enhance overall employee quality[118]. Risk Management - The company faces risks related to industry policy changes, particularly with the implementation of centralized drug procurement, which may impact pricing and profitability[119]. - The company acknowledges potential challenges from rising production costs and stricter environmental regulations, which could affect profitability[119]. - The company is actively addressing R&D risks by focusing on developing diabetes treatment products, which are expected to drive new growth opportunities[119].